MINNEAPOLIS--(BUSINESS WIRE)--Consistent with its commitment to advancing the treatment of cardiovascular disease through innovative product design and rigorous clinical research, Medtronic, Inc. (NYSE: MDT), announced today the start of two new trials of the Endeavor® Resolute drug-eluting stent (DES), the company’s innovative complement to the Endeavor drug-eluting stent, which was approved by the U.S. Food and Drug Administration (FDA) in February 2008.
